TRS TRIMAS CORP Insider Trading

Director Tredwell bought 59 TRS shares at $39.38; 4 of 5 prior TRS buys showed positive 90d returns; stock down -8.2% from 52-week high.

Director Daniel P Tredwell purchased 59 shares of TriMas at $39.38 on 2026-03-05, a modest addition to his 60.5K share position. His transaction history at this ticker shows a pattern of positive timing: 4 of 5 prior buys at TRS resulted in positive 90-day returns, ranging from +13.0% to +43.8%, indicating his prior purchases have consistently preceded periods of stock appreciation. At the current price of $36.75, the stock sits 8.2% below its 52-week high and has gained 8.8% over the past 90 days, a relatively stable backdrop. The company's fundamentals reflect operational headwinds—annual revenue contracted 30.2% year-over-year despite a healthy P/E of 9.88—suggesting this transaction may warrant closer examination of whether prior timing success will persist in a challenged revenue environment.

Director Tredwell buys 73 TRS shares at $31.94; stock down 21.9% from 52-week high, extends 5-buy pattern at ticker with mixed timing.

Tredwell Daniel P, a director at TRIMAS CORP, purchased 73 shares at $31.94 on 2025-11-12, bringing his post-transaction holdings to 60,483 shares. The purchase occurs as the stock trades at $31.24 current price, representing a -21.9% decline from its 52-week high of $40.02, and the stock has declined -14.8% over the prior 30 days and -15.0% over 90 days. This buy extends a pattern of 5 prior purchases at TRS: his prior trades at this ticker show mixed 90-day outcomes (3 of 5 well-timed, with results ranging from -13.6% to +43.8%), and his cross-ticker track record across 11 prior buys averages +6.6% at 90 days with a 63.64% win rate. The small transaction size (+73 shares, +0.1% vs pre-transaction holdings) and the stock's recent price weakness are the key observations in evaluating this purchase alongside the company's fundamentals: P/E of 28.93, $269.3M latest quarterly revenue, and +3.5% annual growth.

Director Fielkow buys 2,000 TRS shares at $31.46; 4 prior TRS purchases all returned +4.4% to +47.2% at 90-day mark.

Director Jeffrey A Fielkow purchased 2,000 shares at $31.46, expanding his TRS holdings by 12.8% to 17,653 shares post-transaction. This is his fifth open-market purchase at this ticker; his prior four TRS buys, spanning from May 2023 to May 2025, each realized positive 90-day returns ranging from +4.4% to +47.2%, with a 100% success rate at the 90-day mark. His cross-ticker track record across all holdings also shows 4 prior buys with an average 90-day return of +22.8% and a 100.00% win rate. The current price of $31.72 sits near the transaction price, -20.7% from the 52-week high and down -14.2% over the past 90 days. The consistent pattern of positive 90-day outcomes across both his TRS-specific history and broader buy history provides a data-grounded reference point for assessing the signal, though the company's elevated P/E of 29.37 and modest recent fundamentals (revenue growth +3.5%, net income $9.3M on $269.3M revenue) warrant investor monitoring of near-term execution.

Director Tredwell Daniel P buys 66 TRS shares at $35.39; stock up 23.7% in 30 days, 51.5% in 90 days.

Tredwell purchased 66 shares at $35.39 on 2025-08-11, adding modestly to a large existing position of 60.3K shares. The stock has appreciated significantly since purchase: +23.7% over 30 days and +51.5% over 90 days, now trading at $37.47, a new 52-week high. His same-ticker history at TRS shows 4 of 5 prior buys were well-timed at the 90-day mark, including three consecutive buys in early 2025 that delivered +11.8%, +12.9%, and +43.8% gains respectively. The latest purchase extends a pattern of consistent, successfully-timed accumulation in this stock, though the modest 66-share transaction size relative to his 60.4K-share position suggests incremental rather than conviction-driven activity.

Director Shapira Adrianne purchased 5,200 shares of TRS for $134,864.40 in two transactions, raising holdings 158.7% to 8,476 shares

Director Adrianne Shapira completed two separate open-market purchases totaling 5,200 shares for $134,864.40 on consecutive days (June 4–5, 2025) at prices ranging from $25.82 to $26.31. This represents a material acquisition, increasing her shareholding by 158.7% from 3,276 to 8,476 shares. The blended purchase price of $25.94 sits 8.4% below the 52-week high of $28.32 and 30% above the 52-week low of $19.90, while the stock has appreciated 6.2% over the past 30 days and 7.0% over 90 days. The company trades at a P/E of 33.26 with modest annual revenue growth of 3.5%, creating a backdrop where the significance of this accumulation lies in the scale of the position increase rather than any dramatic repricing opportunity.

Director SEDAGHAT SHAWN purchased 483,109 shares in 2 transactions for $12,337,985.84 at TRS, raising holdings 34.5% amid cluster buying pattern.

SEDAGHAT SHAWN executed 2 separate purchases totaling 483,109 shares for $12,337,985.84 on consecutive days (2025-05-21 and 2025-05-22) at blended average price $25.54, increasing his holdings from 1,400,649 to 1,883,758 shares (+34.5%). The timing coincides with a broader insider cluster pattern: 2 other insiders also bought within the past 14 days at TRS. This concentrated accumulation by multiple insiders within a compressed window represents a material signal of internal confidence, especially given the director's substantial out-of-pocket commitment at current valuation (P/E 32.59, market cap $1.0B). Notably, the current price ($25.42) sits near the blended transaction prices ($25.54), indicating the trades occurred close to prevailing market levels without opportunistic depth. Investors should monitor whether this multi-insider cluster precedes material developments or earnings revisions.

Director Fielkow buys 500 TRS shares at $24.98; joins 2-insider cluster buy pattern within 14 days.

Fielkow Jeffrey A, a director at TriMas, purchased 500 shares at $24.98 on 2025-05-19, adding to his post-transaction holdings of 15,653 shares. This purchase occurs within a 14-day window in which two other insiders also bought, forming a cluster buy pattern that suggests broader confidence in the stock at current levels. Across his same-ticker history at TRS, Fielkow has executed three prior open-market purchases, with measurable outcomes showing +12.3% at 30 days (2025-02-28 buy) and +11.2% / +11.6% (30-day / 90-day returns) on his 2024-03-04 purchase, indicating a pattern of well-timed entries at this ticker over a 2-year span. The current price of $25.65 is approximately 2.7% above the transaction price and +26.7% over the past 30 days, placing the trade near the upper half of the 52-week range ($19.90–$28.32); the stock remains -9.4% from its 52-week high, suggesting room for further appreciation if the company's quarterly revenue of $241,670,000 and net income of $12,420,000 sustain momentum.

Director Shawn Sedaghat bought 359,357 shares in 3 transactions (May 19-20) at blended avg $25.48, increasing holdings 34.5% to 1,400,649 shares; stock +26.7% in 30d, +10.5% in 90d.

Shawn Sedaghat purchased 359,357 shares across three separate open-market transactions totaling $9,156,433.71, raising his stake from 1,041,292 to 1,400,649 shares. His prior trades at TRS show mixed near-term results (two 30-day declines of -10.8% and -12.3% on March buys), and his cross-ticker track record averages -6.6% 30-day return on 8 prior buys, suggesting limited predictive accuracy for near-term price movement. The company trades at a P/E of 32.88 with modest annual revenue growth of 3.5%, and the stock is currently 9.4% below its 52-week high. A CLUSTER pattern is present—2 other insiders also bought within the past 14 days—which may indicate coordinated or opportunistic positioning, though the muted fundamentals and insider's historical underperformance on timing warrant scrutiny of the underlying rationale.

Director Tredwell bought 94 TRS shares at $24.72; modest accumulation against mixed record.

Director Daniel P Tredwell purchased 94 shares at $24.72 on 2025-05-12, increasing his holdings to 60,343 shares—a 0.2% increase. The transaction size ($2,344.36) is small relative to his existing position, and the purchase occurred while the stock was -14.8% from its 52-week high of $28.32, though up 14.9% over the past 30 days. Tredwell's prior trades at TRS show inconsistent timing: of 5 recent purchases, only 1 of 3 with measurable 90-day outcomes achieved positive returns, with his same-ticker 90-day win rate at 33.3% (1 of 3). His cross-ticker track record shows a 57.14% 90-day win rate across 9 prior buys with an average 90-day return of -0.1%, providing limited predictive signal. The current P/E of 30.92 and fundamentals (revenue $241.7M, net income $12.4M, annual growth +3.5%) appear stable, but the modest position increase and checkered execution history at this ticker offer modest evidence of conviction.

Director Shawn Sedaghat buys 140,318 shares at blended $23.85 for $3.3M, raising stake 15.6% to 1.04M shares.

Director Shawn Sedaghat completed two separate purchases totaling 140,318 shares for $3,346,312.56 at a blended average price of $23.85, increasing his holdings by 15.6% from 900,974 to 1,041,292 shares. The purchases occurred at $23.83 on 2025-04-30 and $23.99 on 2025-05-01, close to the 52-week low of $19.90 and well below the current price of $24.75 and 52-week high of $28.32. His prior same-ticker trades at TRS show mixed near-term performance: five buys from March 2025 with 30-day returns ranging from -12.3% to +2.9%, indicating a pattern of downside volatility following recent entry points. The company trades at a P/E of 31.73 with modest 3.5% annual revenue growth on $241.7M quarterly revenue and $12.4M net income, suggesting a mature-profile business trading near historical valuation peaks.